Michael Witcher

Associate Professor

Lady Davis Institute for Medical Research
Country flagCanada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Michael Witcher is an Associate Professor at The Lady Davis Institute of the Jewish General Hospital, McGill University, Canada. His research primarily focuses on the modulation of mTOR pathways, chromatin remodeling, and the oncogenic functions of CTCF mutations, particularly in the context of cancer biology. Recent publications highlight his contributions to understanding the mechanisms of cancer treatment, including the use of BET inhibitors and the response of triple-negative breast cancers to PARP inhibitors.

Articles (7)

While most individuals with familial medullary thyroid carcinoma (fMTC) carry RET mutations, in some instances the causative mutations remain unknown. We studied two related families with RET-negative fMTC in 21 affected individuals through linkage analysis, exome/genome sequencing, and high-density array comparative genomic hybridization. We identified a novel heterozygous 40kb intragenic SLC30A9 deletion which segregated with the disease in all affected individuals. The mutant transcript escaped nonsense-mediated decay and resulted in the production of N-terminally truncated proteins via translation reinitiation from in-frame AUG codons located downstream of the deletion. These proteins showed increased stability and their expression in an MTC cell line increased cell proliferation and clonogenic capacity, supporting an oncogenic role. These findings expand the genetic background of fMTC beyond RET mutations and implicate translation reinitiation in the etiology of cancer susceptibility syndromes secondary to structural genomic variants.

Year:

2026

Year:

2024

The pogo transposable element–derived zinc finger protein, POGZ, is notably associated with neurodevelopmental disorders through its role in gene transcription. Many proteins involved in neurological development are often dysregulated in cancer, suggesting a potential role for POGZ in tumor biology. Here, we provided experimental evidence that POGZ influences the growth and metastatic spread of triple-negative breast cancers (TNBC). In well-characterized models of TNBC, POGZ exerted a dual role, both as a tumor promoter and metastasis suppressor. Mechanistically, loss of POGZ potentiated TGFβ pathway activation to exert cytostatic effects while simultaneously increasing the mesenchymal and migratory properties of breast tumors. Although POGZ levels are elevated in human breast cancers, the most aggressive forms of TNBC tumors, including those with increased mesenchymal and metastatic properties, exhibit dampened POGZ levels, and low POGZ expression was associated with inferior clinical outcomes in these tumor types. Taken together, these data suggest that POGZ is a critical suppressor of the early stages of the metastatic cascade. Significance: The POGZ neurodevelopmental protein plays dual functions in triple-negative breast cancers as a tumor promoter and metastasis suppressor, inhibiting TGFβ-regulated EMT to limit breast cancer metastatic progression.

Year:

2024

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (19)

Alexandre Orthwein

Assistant Professor

Emory University School of Medicine

UNITED STATES
View details

Federica Begalli

Lecturer in Endocrinology

Queen Mary University of London

UNITED KINGDOM
View details

William Foulkes

Full Professor

McGill University

CANADA
View details

Marton Doleschall

senior scientist

Semmelweis University

HUNGARY
View details

Horia Constantin Stanescu

University College London

UNITED KINGDOM
View details

Maralyn Druce

-

UNITED KINGDOM
View details

Jolanta Krajewska

Associate Professor

Maria Sklodowska-Curie Institute - Oncology Center Gliwice Branch

POLAND
View details

Anne Barlier

Aix-Marseille University

FRANCE
View details

Maria Alevizaki

Professor of Endocrinology

National and Kapodistrian University of Athens

GREECE
View details

Sabrina Chiloiro

Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia

ITALY
View details

Márta Korbonits

Deputy Director of the William Harvey Research Institute

Queen Mary University of London

UNITED KINGDOM
View details

Donato Iacovazzo

NIHR Clinical Lecturer

Queen Mary University of London

UNITED KINGDOM
View details

Malgorzata Oczko-Wojciechowska

Head of Department/Ph.D

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND
View details

Jes Mathiesen

University of Southern Denmark

DENMARK
View details

Claudia Kleinman

Professor

McGill University

CANADA
View details

R Mihai

Oxford University Hospitals NHS Foundation Trust

UNITED KINGDOM
View details

Suvi Savola

Head of Oncogenetics

MRC-Holland

NETHERLANDS
View details

James R. Lupski

-

UNITED STATES
View details

Miklós Tóth

professor

Semmelweis University

HUNGARY
View details